Clinical application of urinary proteomics/peptidomics

References

• Grodos D, Tonglet R. Scandinavian simvastatin study (4S). Lancet344(8939–8940), 1768–1769 (1994).
   Google Scholar
• Sicree R, Shaw J,Zimmet P. Diabetes and impared glucose tolerance. In: Diabetes Atlas. Gan D (Ed.). International Diabetes Federation, Brussels, Belgium, 15–109 (2006).
   Google Scholar
• Fliser D, Novak J, Thongboonkerd V et al. Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol.18(4), 1057–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Fung ET. A recipe for proteomics diagnostic test development: The OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem.56(2), 327–329 (2010).
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst.97(4), 315–319 (2005).
   PubMed Web of Science ®Google Scholar
• Rhea JM, Molinaro RJ. Cancer biomarkers: surviving the journey from bench to bedside. (cover story). Med. Lab. Obs.43(3), 10–18 (2011).
   Google Scholar
• Mischak H, Allmaier G, Apweiler R et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med.2(46), 46ps42 (2010).
   PubMed Web of Science ®Google Scholar
• Mathivanan S, Ahmed M, Ahn NG et al. Human Proteinpedia enables sharing of human protein data. Nat. Biotechnol.26(2), 164–167 (2008).
   PubMed Web of Science ®Google Scholar
• Weissinger EM, Schiffer E, Hertenstein B et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood109(12), 5511–5519 (2007).
   PubMed Web of Science ®Google Scholar
• Weissinger EM, Mischak H. Application of proteomics to posttransplantational follow-up. Methods Mol. Med.134, 217–228 (2007).
   PubMedGoogle Scholar
• Mischak H, Rossing P. Proteomic biomarkers in diabetic nephropathy – reality or future promise? Nephrol. Dial. Transplant.25(9), 2843–2845 (2010).
   Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics1(11), 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Thongboonkerd V. Urinary proteomics: towards biomarker discovery, diagnostics and prognostics. Mol. Biosyst.4, 810–815 (2008).
   PubMedGoogle Scholar
• Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J. Proteome Res.10(1), 5–16 (2010).
   Google Scholar
• Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv. Chronic Kidney Dis.17(6), 493–506 (2010).
   PubMed Web of Science ®Google Scholar
• Rossing K, Mischak H, Dakna M et al. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol.19(7), 1283–1290 (2008).
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Schiffer E, Bauer HW et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin. Appl.2(4), 556–570 (2008).
   PubMed Web of Science ®Google Scholar
• Strong KJ, Osicka TM, Comper WD. Urinary-peptide excretion by patients with and volunteers without diabetes. J. Lab. Clin. Med.145(5), 239–246 (2005).
   Google Scholar
• Brenner BM, Rector F, Levine S. The Kidney (7th Edition). Saunders HJ (Ed.). Elsevier, PA, USA (2004).
   Google Scholar
• Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int.65(1), 323–332 (2004).
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol.7(3), 230–240 (2006).
   PubMed Web of Science ®Google Scholar
• Mischak H, Kolch W, Aivalotis M et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin. Appl.4(4), 464–478 (2010).
   PubMed Web of Science ®Google Scholar
• Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery? J. Proteome Res.6, 3371–3376 (2007).
   PubMed Web of Science ®Google Scholar
• Segal MB. The Choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell. Mol. Neurobiol.20(2), 183–196 (2000).
   PubMed Web of Science ®Google Scholar
• Teng PN, Bateman NW, Hood BL, Conrads TP. Advances in proximal fluid proteomics for disease biomarker discovery. J. Proteome Res.9(12), 6091–6100 (2010).
   PubMed Web of Science ®Google Scholar
• Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis26(7–8), 1476–1487 (2005).
   PubMed Web of Science ®Google Scholar
• Palmblad M, Tiss A, Cramer R. Mass spectrometry in clinical proteomics – from the present to the future. Proteomics Clin. Appl.3(1), 6–17 (2009).
   PubMed Web of Science ®Google Scholar
• Mischak H, Schanstra JP. CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin. Appl.5(1–2), 9–23 (2011).
   PubMed Web of Science ®Google Scholar
• Liotta LA, Petricoin EF. Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit. Clin. Chem.56(10), 1641–1642 (2010).
   PubMed Web of Science ®Google Scholar
• Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom. Rev.28(5), 703–724 (2009).
   PubMed Web of Science ®Google Scholar
• Metzger J, Luppa PB, Good DM, Mischak H. Adapting mass spectrometry-based platforms for clinical proteomics applications: the capillary electrophoresis coupled mass spectrometry paradigm. Crit. Rev. Clin. Lab. Sci.46(3), 129–152 (2009).
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem.54(1), 53–60 (2008).
   PubMed Web of Science ®Google Scholar
• Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev.24(6), 959–977 (2005).
   PubMed Web of Science ®Google Scholar
• Zurbig P, Renfrow MB, Schiffer E et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis27(11), 2111–2125 (2006).
   PubMed Web of Science ®Google Scholar
• Collier TS, Sarkar P, Rao B, Muddiman DC. Quantitative top-down proteomics of SILAC labeled human embryonic stem cells. J. Am. Soc. Mass Spectrom.21(6), 879–889 (2010).
   Google Scholar
• Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Meth.7(5), 383–385 (2010).
   PubMed Web of Science ®Google Scholar
• Collier TS, Sarkar P, Franck WL, Rao BM, Dean RA, Muddiman DC. Direct comparison of stable isotope labeling by amino acids in cell culture and spectral counting for quantitative proteomics. Anal. Chem.82(20), 8696–8702 (2010).
   PubMed Web of Science ®Google Scholar
• Jantos-Siwy J, Schiffer E, Brand K et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J. Proteome Res.8(1), 268–281 (2009).
   PubMed Web of Science ®Google Scholar
• Lapolla A, Seraglia R, Molin L et al. Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephropathic patients: a MALDI study. J. Mass Spectrom.44(3), 419–425 (2009).
   Google Scholar
• Delles C, Schiffer E, von Zur MC et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J. Hypertens.28(11), 2316–2322 (2010).
   PubMed Web of Science ®Google Scholar
• Good DM, Zurbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics9(11), 2424–2437 (2010).
   PubMed Web of Science ®Google Scholar
• Lapolla A, Molin L, Sechi A et al. A further investigation on a MALDI-based method for evaluation of markers of renal damage. J. Mass Spectrom.44(12), 1754–1760 (2009).
   PubMed Web of Science ®Google Scholar
• Kaiser T, Wittke S, Just I et al. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis25(13), 2044–2055 (2004).
   PubMed Web of Science ®Google Scholar
• Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics6(20), 5615–5627 (2006).
   PubMed Web of Science ®Google Scholar
• Dakna M, Harris K, Kalousis A et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics11(1), 594 (2010).
   PubMed Web of Science ®Google Scholar
• Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol.7(9), R80 (2006).
   PubMed Web of Science ®Google Scholar
• Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R, Steen H. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin. Appl.3(9), 1052–1061 (2009).
   PubMed Web of Science ®Google Scholar
• Good DM, Thongboonkerd V, Novak J et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J. Proteome Res.6(12), 4549–4555 (2007).
   PubMed Web of Science ®Google Scholar
• Lapolla A, Tubaro M, Fedele D et al. A matrix-assisted laser desorption/ionization mass spectrometry study of the non-enzymatic glycation products of human globins in diabetes. Rapid Comm. Mass Spectrom.19(2), 162–168 (2005).
   Google Scholar
• Chalmers MJ, Mackay CL, Hendrickson CL et al. Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal. Chem.77(22), 7163–7171 (2005).
   PubMed Web of Science ®Google Scholar
• Renfrow M.B., Cooper HJ, Tomana M et al. Determination of aberrant O-glycosilation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry. J. Biol. Chem.280, 19136–19145 (2005).
   PubMed Web of Science ®Google Scholar
• Renfrow M.B., Mackay CL, Chalmers MJ et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. Anal. Bioanal. Chem.389, 1397–1407 (2007).
   PubMed Web of Science ®Google Scholar
• Olsen JV, Macek B, Lange O, Makarov A, Horning S, Mann M. Higher-energy C-trap dissociation for peptide modification analysis. Nat. Methods4(9), 709–712 (2007).
   PubMed Web of Science ®Google Scholar
• Knepper MA. Common sense approaches to urinary biomarker study design. J. Am. Soc. Nephrol.20(6), 1175–1178 (2009).
   Google Scholar
• LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J. Proteome Res.4(4), 1053–1059 (2005).
   PubMed Web of Science ®Google Scholar
• Alkhalaf A, Zurbig P, Bakker SJ et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One5(10), e13421 (2010).
   PubMed Web of Science ®Google Scholar
• Zimmerli LU, Schiffer E, Zürbig P et al. Urinary proteomics biomarkers in coronary artery disease. Mol. Cell. Proteomics7(2), 290–298 (2008).
   PubMed Web of Science ®Google Scholar
• Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology245(3), 219–223 (2008).
   PubMed Web of Science ®Google Scholar
• Manolis E, Vamvakas S, Isaac M. New pathway for qualification of novel methodologies in the European medicines agency. Proteomics Clin. Appl.5(5–6), 367–374 (2011).
   Google Scholar
• Khoury MJ, Gwinn M, Ioannidis JPA. The emergence of translational epidemiology: from scientific discovery to population health impact. Am. J. Epidemiol.172(5), 517–524 (2010).
   PubMed Web of Science ®Google Scholar
• Butler D. Translational research: crossing the valley of death. Nature453, 840–842 (2008).
   PubMed Web of Science ®Google Scholar
• Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int.65(6), 2426–2434 (2004).
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J. Am. Soc. Nephrol.17(7), 2034–2047 (2006).
   PubMed Web of Science ®Google Scholar
• Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM. The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin. Appl.2(7–8), 997–1007 (2008).
   Web of Science ®Google Scholar
• Rossing P. The changing epidemiology of diabetic microangiopathy in Type 1 diabetes. Diabetologia48(8), 1439–1444 (2005).
   Google Scholar
• Haller H, Ito S, Izzo JL et al. Olmesartan for the delay or prevention of microalbuminuria in Type 2 diabetes. N. Engl. J. Med.364(10), 907–917 (2011).
   PubMed Web of Science ®Google Scholar
• Ameur RB, Molina L, Bolvin C et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol. Dial. Transplant.25, 2866–2875 (2010).
   Google Scholar
• Merchant ML, Perkins BA, Boratyn GM et al. Urinary peptidome may predict renal function decline in Type 1 diabetes and microalbuminuria. J. Am. Soc. Nephrol.20(9), 2065–2074 (2009).
   PubMed Web of Science ®Google Scholar
• Haubitz M, Good DM, Woywodt A et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in ANCA associated vasculitis. Mol. Cell. Proteomics8, 2296–2307 (2009).
   PubMed Web of Science ®Google Scholar
• Haubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int.67(6), 2313–2320 (2005).
   PubMed Web of Science ®Google Scholar
• Julian BA, Wittke S, Novak J et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis28(23), 4469–4483 (2007).
   PubMed Web of Science ®Google Scholar
• Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, Serra AL. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int.76(1), 89–96 (2009).
   Web of Science ®Google Scholar
• Decramer S, Wittke S, Mischak H et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med.12(4), 398–400 (2006).
   PubMed Web of Science ®Google Scholar
• Decramer S, Zürbig P, Wittke S, Mischak H, Bascands JL, Schanstra JP. Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy. Contrib. Nephrol.160, 127–141 (2008).
   PubMed Web of Science ®Google Scholar
• Coca SG, Parikh CR. Urinary biomarkers for acute kidney injury: perspectives on translation. Clin. J. Am. Soc. Nephrol.3(2), 481–490 (2008).
   PubMed Web of Science ®Google Scholar
• Herget-Rosenthal S, Marggraf G, Husing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int.66(3), 1115–1122 (2004).
   PubMed Web of Science ®Google Scholar
• Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet365(9466), 1231–1238 (2005).
   PubMed Web of Science ®Google Scholar
• Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J. Am. Soc. Nephrol.16(10), 3046–3052 (2005).
   PubMed Web of Science ®Google Scholar
• Han WK, Waikar SS, Johnson A et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int.73(7), 863–869 (2008).
   PubMed Web of Science ®Google Scholar
• Haase M, Bellomo R, Story D, Davenport P, Haase-Fielitz A. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit. Care12(4), R96 (2008).
   PubMed Web of Science ®Google Scholar
• Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am. J. Kidney Dis.52(3), 425–433 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou H, Pisitkun T, Aponte A et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int.70(10), 1847–1857 (2006).
   PubMed Web of Science ®Google Scholar
• Metzger J, Kirsch T, Schiffer E et al. Diagnostic marker pattern of sequenced urinary peptides for early and accurate detection of acute kidney injury. Kidney Int.78(12), 1252–1262 (2010).
   PubMed Web of Science ®Google Scholar
• Rush DN, Nickerson P, Jeffery JR, McKenna RM, Grimm PC, Gough J. Protocol biopsies in renal transplantation: research tool or clinically useful? Curr. Opin. Nephrol. Hypertens.6(7), 691–694 (1998).
   Google Scholar
• Schaub S, Wilkins JA, Antonovici M et al. Proteomic-based identification of cleaved urinary β2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant5(4 Pt 1), 729–738 (2005).
   PubMed Web of Science ®Google Scholar
• Wittke S, Haubitz M, Walden M et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am. J. Transplant5(10), 2479–2488 (2005).
   PubMed Web of Science ®Google Scholar
• Sigdel T, Kaushal A, Gritsenko M et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin. Appl.4, 32–47 (2010).
   PubMed Web of Science ®Google Scholar
• Gwinner W, Hinzmann K, Erdbruegger U et al. Acute tubular injury in protocol biopsies of renal grafts: prevalence, associated factors and effect on long-term function. Am. J. Transplant8(8), 1684–1693 (2008).
   PubMed Web of Science ®Google Scholar
• Ling XB, Sigdel TK, Lau K et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J. Am. Soc. Nephrol.21(4), 646–653 (2010).
   PubMed Web of Science ®Google Scholar
• Metzger J, Chatzikyrkou C, Broecker V et al. Diagnosis of subclinical and clinical acute T-cell mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin. Appl.5(5–6), 322–333 (2011).
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med.360(13), 1320–1328 (2009).
   PubMed Web of Science ®Google Scholar
• Siddiqui E, Mumtaz FH, Gelister J. Understanding prostate cancer. J. Royal Soc. Prom. Health124(5), 219–221 (2004).
   Google Scholar
• M’Koma AE, Blum DL, Norris JL et al. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun.353(3), 829–834 (2006).
   Google Scholar
• Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol. Oncol.24(4), 326–337 (2006).
   PubMed Web of Science ®Google Scholar
• Dinney CP, McConkey DJ, Millikan RE et al. Focus on bladder cancer. Cancer Cell6(2), 111–116 (2004).
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schellhammer PF, Mendrinos S et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol.158(4), 1491–1502 (2001).
   PubMed Web of Science ®Google Scholar
• Schiffer E, Vlahou A, Petrolekas A et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res.15(15), 4935–4943 (2009).
   PubMed Web of Science ®Google Scholar
• Sung HJ, Ryang YS, Jang SW, Lee CW, Han KH, Ko J. Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers11(3), 279–290 (2006).
   PubMed Web of Science ®Google Scholar
• You SA, Archacki SR, Angheloiu G et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol. Genomics13(1), 25–30 (2003).
   PubMed Web of Science ®Google Scholar
• Duran MC, Martin-Ventura JL, Mas S et al. Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol. Biol.357, 141–150 (2007).
   PubMedGoogle Scholar
• von Zur Muhlen C., Schiffer E, Zuerbig P et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J. Proteome Res.8(1), 335–345 (2009).
   PubMed Web of Science ®Google Scholar
• Snell-Bergeon JK, Maahs DM, Ogden LG et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol. Ther.11(1), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Maahs DM, Siwy J, Argiles A et al. Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One5(9), e13051 (2010).
   Google Scholar
• Kaiser T, Kamal H, Rank A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood104(2), 340–349 (2004).
   PubMed Web of Science ®Google Scholar
• Carty DM, Siwy J, Brennand JE et al. Urinary proteomics for prediction of preeclampsia. Hypertension57(3), 561–569 (2011).
   PubMed Web of Science ®Google Scholar
• Zürbig P, Decramer S, Dakna M et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics9(8), 2108–2117 (2009).
   PubMed Web of Science ®Google Scholar
• Siwy J, Mullen W, Golovko I, Franke J, Zurbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin. Appl.5(5–6), 367–374 (2011).
   PubMed Web of Science ®Google Scholar
• Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol.16(Suppl. 1), S30–S33 (2005).
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schanstra J, Frokiaer J et al. Establishment of a European network for urine and kidney proteomics. J. Proteomics71(4), 490–492 (2008).
   PubMed Web of Science ®Google Scholar